Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Wall Street Analysts Forecast Growth
FMS has been the subject of several recent analyst reports. Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from an "underperform" rating to a "buy" rating and raised their target price for the company from $30.30 to $33.70 in a research note on Monday, June 27th. StockNews.com downgraded shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 15th. Truist Financial lowered their target price on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating for the company in a research note on Wednesday, June 22nd. JPMorgan Chase & Co. lowered their target price on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research note on Monday, August 1st. Finally, DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "hold" rating in a research note on Friday, July 29th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has an average rating of "Hold" and a consensus target price of $49.01.
Fresenius Medical Care AG & Co. KGaA Trading Down 0.1 %
NYSE:FMS opened at $18.66 on Tuesday. The company has a fifty day simple moving average of $24.13 and a two-hundred day simple moving average of $29.46. The stock has a market cap of $10.94 billion, a P/E ratio of 11.89, a P/E/G ratio of 0.92 and a beta of 1.03. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.16 and a 12-month high of $40.85. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt-to-equity ratio of 0.47.